Literature DB >> 2306520

T lymphocytes from invaded lymph nodes in patients with B-cell-derived non-Hodgkin's lymphoma: reactivity toward the malignant clone.

M C Jacob1, M P Piccinni, T Bonnefoix, M F Sotto, P Couderc, J C Bensa, J J Sotto.   

Abstract

Tumor-infiltrating T lymphocytes (TIL-T) are always present in B-cell-derived non-Hodgkin's lymphoma (NHL). In this investigation, we explored the possibility that collaboration might exist between these cells. TIL-T were isolated from 39 lymph nodes of patients with NHL. In most of the cases, few of them (less than 10%) possessed surface activation receptors CD25 or OKT9. In 80% of the cases, they proliferated in response to recombinant interleukin-2 (rIL-2), but the degree of proliferation was often low as compared with control populations. The influence of irradiated autologous malignant cells on the TIL-T proliferation in response to rIL-2 (40 U/mL) was also investigated: in 38% of the cases, this proliferation was not modified (group O), and in 41% it was higher (group +) and in 21% it was lower (group -). The mechanism of this immune response (specific or not) is not elucidated at present. The definition of these groups was statistically correlated with different parameters of the disease: (1) percentage of TIL-T was higher in group + (44% +/- 17%) than in group O (31% +/- 18%) and group - (24% +/- 15%); (2) B-cell proliferation in centrofollicular lymphomas was more frequently nodular or nodular and diffuse in group + (83%) and O (55%) than in group - (0%); (3) low-grade malignancies in the Working Formulation were more frequent in group + (75%) than in group O (60%) or group - (12%); (4) favorable prognosis evaluated with the Grenoble cytologic classification was more frequent in group + and O (87%) than in group - (12%); (5) actuarial survival curves showed a significantly better prognosis for patients in group +.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2306520

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs.

Authors:  S Agrawal; J Marquet; M H Delfau-Larue; C Copie-Bergman; H Jouault; F Reyes; A Bensussan; J P Farcet
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

2.  Tumour infiltrating T-cells in gastric lymphoma.

Authors:  T Hussell; P G Isaacson; J Spencer
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

3.  Characterization of tumor-infiltrating T lymphocytes in B-cell lymphomas of mucosa-associated lymphoid tissue.

Authors:  A Koulis; T Diss; P G Isaacson; A Dogan
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

Review 4.  Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?

Authors:  Ph Solal-Céligny; X Cahu; G Cartron
Journal:  Int J Hematol       Date:  2010-08-31       Impact factor: 2.490

5.  Responses to T cell receptor/CD3 and interleukin-2 receptor stimulation are altered in T cells from B cell non-Hodgkin's lymphomas.

Authors:  S Kudoh; Q Wang; O F Hidalgo; P Rayman; R R Tubbs; M G Edinger; V Kolenko; J Panuto; R Bukowski; J H Finke
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

6.  Activated T-cell subsets in benign lymphoid hyperplasias and B-cell non-Hodgkin's lymphomas.

Authors:  J I Diaz; M G Edinger; M H Stoler; R R Tubbs
Journal:  Am J Pathol       Date:  1991-09       Impact factor: 4.307

7.  Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy.

Authors:  Alan G Ramsay; Andrew J Clear; Gavin Kelly; Rewas Fatah; Janet Matthews; Finlay Macdougall; T Andrew Lister; Abigail M Lee; Maria Calaminici; John G Gribben
Journal:  Blood       Date:  2009-09-28       Impact factor: 22.113

8.  Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma.

Authors:  F A Vyth-Dreese; H Boot; T A Dellemijn; D M Majoor; L C Oomen; J D Laman; M Van Meurs; R A De Weger; D De Jong
Journal:  Immunology       Date:  1998-08       Impact factor: 7.397

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.